Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

COPD is the third leading cause of death worldwide ... with improvements in lung function and health-related quality of life scores. Regeneron’s chief scientific officer, George Yancopolous ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Some of the early signs of chronic obstructive pulmonary disease (COPD) are an ongoing cough, increased mucus, and fatigue. Recognizing these symptoms is important to know whether you need to see ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

New data from the Florida Department of Health and FDLE shows seniors in the Tampa Bay region are dying at higher rates from ...